Therefore, we decided to study the association among plasma levels of relaxin-2 in LA and peripheral vein of AF patients with molecules implicated in fibrosis, inflammation and oxidative stress, which could be useful for AF risk prediction and could help to identify possible pathways or markers involved in the onset of AF, as well as to evaluate promising therapeutic strategies for AF, such as relaxin-2 or serelaxin treatment. This evidence concerns the gene RLN2 and atrial fibrillation.